Reconstitution Best Practices for Lyophilized Research Peptides

Scope and RUO boundary

Reconstitution converts a lyophilized research material into a solution for controlled laboratory work. It does not change the material category. HALO peptides remain research-use-only after reconstitution and are not intended for human or veterinary use, diagnosis, treatment, compounding, or administration.

The correct procedure depends on the peptide, diluent, concentration, assay endpoint, and institutional SOP. The framework below is a conservative handling model for qualified laboratory environments and should be validated against the lot COA, product insert, and internal study protocol.

Pre-reconstitution checklist

• Confirm product name and lot number against the COA.
• Review expected molecular weight, vial size, and storage notes.
• Select a validated research diluent for the compound and endpoint.
• Define target concentration before opening the vial.
• Prepare labelled aliquot containers before adding diluent.
• Use aseptic technique appropriate to the laboratory environment and study design.

Step-by-step preparation model

1. Equilibrate sealed vial: remove the sealed lyophilized vial from cold storage and allow it to approach room temperature before opening. This reduces condensation risk.
2. Inspect the vial: confirm closure integrity and note the appearance of the lyophilized cake or powder.
3. Calculate volume: target concentration equals peptide mass divided by final volume. A 5 mg vial brought to 1 mg/mL requires 5 mL final volume.
4. Add diluent slowly: introduce liquid down the inner glass wall rather than directly onto the lyophilized cake.
5. Mix gently: swirl or roll until dissolved. Avoid vortexing unless the product-specific SOP has validated it; strong agitation can promote foaming or aggregation.
6. Inspect solution: record clarity, visible particulates, and time to dissolution.
7. Aliquot promptly: divide into study-sized volumes to minimize repeat freeze-thaw cycles and repeated stock-vial entries.
8. Label and log: include compound, lot, concentration, diluent, date, operator initials, and storage condition.

Diluent selection

No single diluent is correct for every peptide or endpoint. Sterile water, bacteriostatic water, buffered systems, weak acid, weak base, or co-solvent systems may appear in research protocols depending on sequence and solubility. Diluent selection should be based on peptide chemistry, assay compatibility, pH requirements, and internal validation. If a lot insert provides compound-specific guidance, it should take priority over general handling assumptions.

A preservative-containing diluent may support short-term refrigerated research storage in some workflows, but it is not a substitute for sterility validation, endotoxin testing, or clinical-use clearance. Those are separate specifications and are not implied by ordinary RUO reconstitution.

Concentration calculation example

Final concentration is calculated with:

Concentration = mass / final volume

For a 10 mg vial, adding final volume of 2 mL produces 5 mg/mL. Adding final volume of 5 mL produces 2 mg/mL. The required concentration should be chosen from the study protocol before preparation so downstream pipetting remains accurate and documented.

Documentation standards

Every reconstitution event should be traceable. At minimum, retain the COA, vial lot, diluent lot, final concentration, preparation date, operator, storage condition, and aliquot map. This record becomes part of the study file and makes it possible to investigate unexpected assay results without guessing which preparation was used.